Overcoming Clinical Inertia in Type 2 Diabetes

Overcoming Clinical Inertia in Type 2 Diabetes is organized by Springer Healthcare IME.

Description:
There are two common reasons for suboptimal glycemic control: firstly, low adherence to medication by the patient and, secondly, the clinician’s failure to initiate or intensify glucose-lowering therapy when it could provide clinical benefit, known as clinical inertia.

Clinical inertia is common, affecting up to 50% of patients with type 2 diabetes. There are many causes of clinical inertia including a lack of confidence in the appropriate use of newer therapies, non-adherence to updated guidelines, and management plans being performed in a traditional, linear way with inefficient communication across specialties and with the patient.

This discussion-based webinar aims to address the causes of clinical inertia and look at strategies to overcome and avoid it.

Learning Objectives:
Following completion of this independent educational program, you will be able to:

• Discuss the causes of therapeutic inertia in type 2 diabetes and ways to overcome it

• Adapt management plans to address cardiometabolic risks independent of HbA1c through a detailed understanding of the CVOT data and up-to-date guidelines

• Debate initiatives to improve multidisciplinary working and shared decision-making in type 2 diabetes care